Serina Therapeutics Surge: Shares of Serina Therapeutics Inc rose 25.3% to $7.07 in pre-market trading following positive FDA feedback on SER-252.
Other Notable Gainers: Invivyd Inc shares increased by 84.1%, Steakholder Foods Ltd gained 62.4%, and Beneficient saw a rise of 55% in pre-market trading.
Significant Losers: ESSA Pharma Inc experienced a sharp decline of 59.8%, while Femasys Inc fell 42.8% after announcing a public offering.
Market Trends: Overall, several stocks showed significant fluctuations in pre-market trading, with both notable gains and losses reported.
SER
$2.99+Infinity%1D
Analyst Views on SER
Wall Street analysts forecast SER stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SER is 13.00 USD with a low forecast of 11.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast SER stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SER is 13.00 USD with a low forecast of 11.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.120
Low
11.00
Averages
13.00
High
15.00
Current: 3.120
Low
11.00
Averages
13.00
High
15.00
H.C. Wainwright
H.C. Wainwright
Buy
initiated
$15
2025-07-14
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$15
2025-07-14
initiated
Buy
Reason
H.C. Wainwright initiated coverage of Serina Therapeutics with a Buy rating and $15 price target. The firm says Serina is an emerging biopharmaceutical company focused on developing next-generation versions of existing active pharmaceutical ingredients.
Jones Trading
Justin Walsh
Strong Buy
Initiates
$11
2025-03-11
Reason
Jones Trading
Justin Walsh
Price Target
$11
2025-03-11
Initiates
Strong Buy
Reason
About SER
Serina Therapeutics Inc. is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. The Company's POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Its proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Its POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. SER-252 is the Company’s lead candidate for advanced Parkinson’s disease. SER-252 is an investigational apomorphine therapy developed with its POZ platform and designed to provide continuous dopaminergic stimulation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
